{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:25:26Z","timestamp":1776785126577,"version":"3.51.2"},"reference-count":38,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"3","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: Chronic hepatitis B (CHB) remains a wide-spread and serious infectious disease, with its pathogenesis still not fully understood. Tenofovir Amibufenamide, a pro-drug of tenofovir, belongs to the class of nucleoside reverse transcriptase inhibitors and is used in the treatment of CHB. This study aimed to evaluate the efficacy and safety of Tenofovir Amibufenamide in treating HBeAg-positive CHB. Methods: A total of 60 patients diagnosed with HBeAg-positive CHB were randomly assigned to two groups: an entecavir (ETV) group (0.5 mg) and a Tenofovir Amibufenamide (TMF) group (0.25 mg), with 30 patients in each. After 24 months of treatment, renal function (serum creatinine, glomerular filtration rate), liver function (ALT , AST , total bilirubin), and inflammatory markers (TNF-a levels) were measured to assess the antiviral efficacy and safety profiles of the two treatments. Results: Patients in the TMF group exhibited smaller changes in serum creatinine and glomerular filtration rate, indicating less renal impairment compared to the ETV group. Furthermore, the TMF group demonstrated greater reductions in alanine aminotransferase (ALT) and total bilirubin (TBIL) levels, indicating superior improvement in liver function (P&lt;0.05). TNF-a levels were significantly elevated in the ETV group, reflecting greater inflammatory activity, while the TMF group showed more controlled inflammation. Additionally, the TMF group experienced significantly lower hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA levels, showing superior antiviral efficacy. The incidence of adverse reactions was lower in the TMF group (3.3%) compared to the ETV group (13.3%), although the difference was not statistically significant (P&gt;0.05). Conclusions: Tenofovir Amibufenamide demonstrated superior efficacy in improving liver function and reducing viral load in patients with HBeAg-positive CHB. Moreover, it had a minimal impact on renal function and presented a higher safety profile compared to entecavir. These findings suggest Tenofovir Amibufenamide as a promising alternative for the treatment of HBeAg-positive CHB.<\/jats:p>","DOI":"10.5937\/jomb0-56238","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:47:30Z","timestamp":1741258050000},"page":"687-695","source":"Crossref","is-referenced-by-count":1,"title":["Serum TNF-a and biomarkers levels after tenofovir therapy in patients with serum HBeAg-positive chronic hepatitis B"],"prefix":"10.5937","volume":"44","author":[{"given":"Xijie","family":"Lai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiunong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Fatemipour M, Arabzadeh SAM, Molaei H, Geramizadeh B, Dabiri S, Fatemipour B, Vahedi SM, Malekpour Afshar R. Evaluation of STAT3 rs1053004 single nucleotide polymorphism in patients with chronic hepatitis B and hepatocellular carcinoma. Cellular and Molecular Biology (Noisy-le-Grand, France) 2017; 63(12): 45-50;","DOI":"10.14715\/10.14715\/cmb\/2017.63.12.11"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clinical Microbiology Reviews 2020; 33(2): e00046-19;","DOI":"10.1128\/CMR.00046-19"},{"key":"ref3","unstructured":"Wilkins T, Sams R, Carpenter M. Hepatitis B: screening, prevention, diagnosis, and treatment. American Family Physician 2019; 99(5): 314-23;"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Marrone A, Ciotti M, Rinaldi L, Adinolfi LE, Ghany M. Hepatitis B and C virus infection and risk of haematological malignancies. Journal of Viral Hepatitis 2020; 27(1): 4-12;","DOI":"10.1111\/jvh.13183"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Loggi E, Gitto S, Gabrielli F, Franchi E, Seferi H, Cursaro C, Andreone P. Virological treatment monitoring for chronic hepatitis B. Viruses 2022; 14(7): 1376(1-14);","DOI":"10.3390\/v14071376"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Tong J, Ye T, Yang XF, Peng H, Xiao X, Xie BJ, Wan ZQ, Li W, Zhou L, Chen J, Guo JJ. HBeAg precursor proteins interact with APOBEC3A and inhibit HBV replication. Journal of Biological Regulators and Homeostatic Agents 2023; 37(3): 1361-70;","DOI":"10.23812\/j.biol.regul.homeost.agents.20233703.136"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Liu SH, Seto WK, Lai CL, Yuen MF. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology & Hepatology 2016; 10(6): 697-707;","DOI":"10.1586\/17474124.2016.1145547"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Li L, Zhou J, Li Y, Wang F, Zhang D, Wang M, Tao Y, Chen E. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study. Frontiers in Pharmacology 2023; 14: 1165990(1-12);","DOI":"10.3389\/fphar.2023.1165990"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Wu Q, Pan C, Jia W, Li C, Sun C, Niu J, Hou J; TMF Study Group. 96-Week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients. Journal of Clinical and Translational Hepatology 2023; 11(3): 649-60;","DOI":"10.14218\/JCTH.2022.00058"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hong X, Cai Z, Zhou F, Jin X, Wang G, Ouyang B, Zhang J. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. Frontiers in Pharmacology 2022; 13: 932934(1-17);","DOI":"10.3389\/fphar.2022.932934"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics 2021; 54(9): 1134-49;","DOI":"10.1111\/apt.16611"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Chang ML, Liaw YF. Hepatitis B flare in hepatitis B e antigen-negative patients: a complicated cascade of innate and adaptive immune responses. International Journal of Molecular Sciences 2022; 23(3): 1552(1-23);","DOI":"10.3390\/ijms23031552"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Xing T, Xu H, Cao L, Ye M. HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term nucleos(t)ide analog treatment: a systematic review and network meta-analysis. PLoS One 2017; 12(1): e0169444(1-18);","DOI":"10.1371\/journal.pone.0169444"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Chu YJ, Jeng WJ, Pan MH, Hu HH, Luo WS, Su CY, Chiang CT, Jen CL, Chen CJ, Yang HI. Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B. Journal of Gastroenterology 2022; 57(6): 423-32;","DOI":"10.1007\/s00535-022-01874-8"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, \u00c7elen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of Hepatology 2018; 68(4): 672-81;","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Van B\u00f6mmel F, Berg T. Risks and Benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic hepatitis B. Hepatology Communications 2021; 5(10): 1632-48;","DOI":"10.1002\/hep4.1708"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Tovo CV, Ahlert M, Panke C, de Mattos \u00c2Z, de Mattos AA. Treatment of hepatitis B virus infection in chronic infection with HBeAg-positive adult patients (immunotolerant patients): a systematic review. European Journal of Gastroenterology & Hepatology Publish Ahead of Print 2021; 33(5): 605-9;","DOI":"10.1097\/MEG.0000000000001907"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tan DJH, Ng CH, Tay PWL, Syn N, Muthiah MD, Lim WH, Tang ASP, Lim KE, Lim GEH, Tamaki N, Kim BK, Teng MLP, Fung J, Loomba R, Nguyen MH, Huang DQ. Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis. JAMA Network Open 2022; 5(6): e2219407(1-15);","DOI":"10.1001\/jamanetworkopen.2022.19407"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. The New-England Medical Review and Journal 2018; 378(10): 911-23;","DOI":"10.1056\/NEJMoa1708131"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Atilla A, Takin MH, Kazak Z, Ayd\u0131n S, K\u0131l\u0131\u00e7 SS. GP73 level in patients with chronic hepatitis B: Relationship with liver biopsy, levels of ALT, AST and HBV DNA. Indian Journal of Pathology & Microbiology 2022; 65(1): 55-8;","DOI":"10.4103\/IJPM.IJPM_1149_20"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Makita T, Kanzaki H, Onishi H, Ikeda A, Takaki A, Wada N, Takeuchi Y, Yasunaka T, Ikeda F, Shiraha H, Tanaka Y, Nishihara S, Murakawa K, Kitamura Y, Okada H, Sendo T. Adefovir dipivoxil-induced fanconi's syndrome and osteomalacia following multiple bone fractures in a patient with chronic hepatitis B. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan 2019; 139(4): 641-5;","DOI":"10.1248\/yakushi.18-00170"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Li J, Hu C, Chen Y, Zhang R, Fu S, Zhou M, Gao Z, Fu M, Yan T, Yang Y, Li J, Liu J, Chen T, Zhao Y, He Y. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. BMC Infectious Diseases 2021; 21(1): 567(1-9);","DOI":"10.1186\/s12879-021-06237-x"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Jung CY, Kim HW, Ahn SH, Kim SU, Kim BS. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B. Liver International: Official Journal of the International Association for the Study of the Liver 2022; 42(5): 1017-26;","DOI":"10.1111\/liv.15208"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yap DY, Yung S, Tang CS, Seto WK, Ma MK, Mok MM, Kwan LP, Chan GC, Choy BY, Yuen MF, Chan TM. Entecavir treatment in kidney transplant recipients infected with hepatitis B. Clinical Transplantation 2014; 28(9): 1010-5;","DOI":"10.1111\/ctr.12410"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Tsai MC, Chang KC, Yen YH, Wu CK, Lin MT, Hu TH. Comparison of tenofovir and entecavir in the development of acute kidney injury in cirrhotic chronic hepatitis B patients with refractory ascites. European Journal of Gastroenterology & Hepatology Publish Ahead of Print 2021; 32(2): 208-13;","DOI":"10.1097\/MEG.0000000000001711"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Law ST, Li KK, Ho YY. Acquired fanconi syndrome associated with prolonged adefovir dipivoxil therapy in a chronic hepatitis B patient. American Journal of Therapeutics 2013; 20(6): e713-6;","DOI":"10.1097\/MJT.0b013e31820c4b20"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Wong GL, Wen WH, Pan CQ. Hepatitis b-management of acute infection and active inflammation in pregnancy-a hepatologist's perspective. Best Practice & Research. Clinical Obstetrics & Gynaecology 2020; 68: 54-65;","DOI":"10.1016\/j.bpobgyn.2020.03.014"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Saxena R, Kaur J. Th1\/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma. World Journal of Hepatology 2015; 7(11): 1572-80;","DOI":"10.4254\/wjh.v7.i11.1572"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Sominskaya I, Skrastina D, Petrovskis I, Dishlers A, Berza I, Mihailova M, Jansons J, Akopjana I, Stahovska I, Dreilina D, Ose V, Pumpens P. A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1\/Th2 switch in the immune responses of mice. PLoS One 2013; 8(9): e75938(1-13);","DOI":"10.1371\/journal.pone.0075938"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"El Jamaly H, Eslick GD, Weltman M. Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. Alimentary Pharmacology & Therapeutics 2022; 56(7): 1104-18;","DOI":"10.1111\/apt.17155"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Talaat RM, Abdelkhalek MS, El-Maadawy EA, Abdel-Mageed WS, El-Shenawy SZ, Osman MA. Association of TNF-Alpha gene polymorphisms and susceptibility to hepatitis B virus infection in egyptians. Human Immunology 2017; 78(11-12): 739-46;","DOI":"10.1016\/j.humimm.2017.10.006"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Shiue SJ, Cheng CL, Shiue HS, Chen CN, Cheng SW, Wu LW, Jargalsaikhan G, Chan TS, Lin HY, Wu MS. Arthrospira enhances seroclearance in patients with chronic hepatitis B receiving nucleos(t)ide analogue through modulation of TNF-a\/IFN-g profile. Nutrients 2022; 14(14): 2790(1-16);","DOI":"10.3390\/nu14142790"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Park YK, Park ES, Kim DH, Ahn SH, Park SH, Lee AR, Park S, Kang HS, Lee JH, Kim JM, Lee SK, Lim KH, Isorce N, Tong S, Zoulim F, Kim KH. Cleaved c-FLIP mediates the antiviral effect of TNF-a against hepatitis B virus by dysregulating hepatocyte nuclear factors. Journal of Hepatology 2016; 64(2): 268-77;","DOI":"10.1016\/j.jhep.2015.09.012"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Suhail M, Abdel-Hafiz H, Ali A, Fatima K, Damanhouri GA, Azhar E, Chaudhary AG, Qadri I. Potential mechanisms of hepatitis B virus induced liver injury. World Journal of Gastroenterology 2014; 20(35): 12462-72;","DOI":"10.3748\/wjg.v20.i35.12462"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Bacaks\u0131z F, G\u00f6kcan H, Akdo\u011fan M, G\u00f6k\u00e7e DT, Ar\u0131 D, G\u00f6kbulut V, Erg\u00fcn Y, \u00d6zt\u00fcrk \u00d6, Kacar S. Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients. International Journal of Clinical Practice 2021; 75(12): e14899(1-6);","DOI":"10.1111\/ijcp.14899"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Perrillo R, Lin HS, Schwarz KB, Rosenthal P, Lisker-Melman M, Chung RT, Prokunina-Olsson L, Cloherty G, Feld J; Hepatitis B Research Network (HBRN). Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. Hepatology (Baltimore, Md.) 2022; 76(3): 775-87;","DOI":"10.1002\/hep.32400"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Chang X, Wang J, Chen Y, Long Q, Song L, Li Q, Liu H, Shang Q, Yu Z, Jiang L, Xiao G, Li L, Chen L, Wang X, Li Z, Chen D, Dong Z, An L, Tan L, Chen Y, Yang Y. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine 2021; 67: 103389(1-11);","DOI":"10.1016\/j.ebiom.2021.103389"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Li M, Zhang L, Xie S, Sun F, Zeng Z, Deng W, Jiang T, Bi X, Lin Y, Yang L, Lu Y, Shen G, Liu R, Wu S, Chang M, Hu L, Dong J, Yi W, Xie Y. Dynamic changes of cytokine profiles and virological markers associated with HBsAg loss during peginterferon alpha-2a treatment in HBeAg-positive chronic hepatitis B patients. Frontiers in Immunology 2022; 13: 892031(1-11);","DOI":"10.3389\/fimmu.2022.892031"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Nivoi TNF-a i biomarkera u serumu nakon terapije tenofovirom kod pacijenata sa hroni\u010dnim hepatitisom B pozitivnim na HBeAg"],"language":"en","link":[{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582503687L.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T16:47:02Z","timestamp":1749833222000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582503687L"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-56238","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}